Uplizna (inebilizumab-cdon) Manufactured by Viela Biois a CD19-directed cytolytic antibody.
Uplizna is specifically indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Uplizna is supplied as an injection for intravenous administration. Hepatitis B virus, quantitative serum immunoglobulins, and tuberculosis screening is required before the first dose. Prior to every infusion: determine if there is an active infection and premedicate with a corticosteroid, an antihistamine, and an antipyretic. Uplizna must be diluted in 250 mL of 0.9% Sodium Chloride Injection, USP prior to administration. Uplizna is administered as an intravenous infusion titrated to completion, approximately 90 minutes. The recommended dose is:
- Initial dose: 300 mg intravenous infusion followed two weeks later by a second 300 mg intravenous infusion
- Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months
Monitor patients closely during the infusion and for at least one hour after completion of the infusion.